$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Will the side effects of ceritinib disappear? How to take ceritinib effectively?
2025-10-19 11:44:20
Check Details
Can the dose of alectinib be reduced due to serious side effects? How effective is alectinib?
2025-10-19 11:44:20
Check Details
How to alleviate the side effects of crizotinib? What are the precautions for crizotinib?
2025-10-19 11:44:20
Check Details
What are the common side effects of osimertinib and how to deal with them? How many years can I take osimertinib for the longest time?
2025-10-19 11:44:20
Check Details
What are the common adverse reactions of dacomitinib (Dozerun)? What to pay attention to
2025-10-19 11:44:20
Check Details
Can the dose of dacomitinib be adjusted due to serious side effects? What are the taboos and precautions?
2025-10-19 11:44:20
Check Details
What are the adverse reactions of bochitinib? What should you pay attention to during treatment
2025-10-19 11:44:20
Check Details
What are the side effects of bochitinib in treating lung cancer? How long does it take for resistance to bochitinib to develop?
2025-10-19 11:44:20
Check Details
What are the side effects and precautions of Tepotinib Hydrochloride Tablets?
2025-10-19 11:44:20
Check Details
What are the side effects of Aletinib (Aletinib)? What are the precautions
2025-10-19 11:44:20
Check Details
What are the common adverse reactions of osimertinib? What should you pay attention to when using it
2025-10-19 11:44:20
Check Details
What are the common adverse reactions of afatinib (Gitari)? What are the precautions
2025-10-19 11:44:20
Check Details
1
2
...
4100
4101
4102
4103
4104
4105
4106
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
2
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
3
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
4
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
5
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
6
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
7
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
8
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
9
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
10
Vemurafenib (Zelboraf) Complete Medication Guide
11
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
12
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer